In one trial to treat advanced NSCLC (NCT02793856), plasmids encoding Cas9 and sgRNA were electroporated into autologous primary T cells to disrupt genomic PD-1 expression. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.